m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00661)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
PEG10
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) [READER]
Representative RNA-seq result indicating the expression of this target gene regulated by IGF2BP1 | ||
Cell Line | ES-2 cell line | Homo sapiens |
Treatment: siIGF2BP1 ES-2 cells
Control: siControl ES-2 cells
|
GSE161087 | |
Regulation |
|
logFC: 1.77E+00 p-value: 9.40E-06 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | IGF2BP1 expression increased in EC, and high expression of this protein correlated with poor prognosis. IGF2BP1 can recognize m6A sites in the 3'UTR of PEG10 mRNA and recruits PABPC1 to enhance Retrotransposon-derived protein PEG10 (PEG10) mRNA stability, which consequently promotes PEG10 protein expression. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Endometrial cancer | ICD-11: 2C76 | ||
In-vitro Model | RL95-2 | Endometrial adenosquamous carcinoma | Homo sapiens | CVCL_0505 |
KLE | Endometrial adenocarcinoma | Homo sapiens | CVCL_1329 | |
Ishikawa | Endometrial adenocarcinoma | Homo sapiens | CVCL_2529 | |
HEC-1-B | Endometrial adenocarcinoma | Homo sapiens | CVCL_0294 | |
HEC-1-A | Endometrial adenocarcinoma | Homo sapiens | CVCL_0293 | |
AN3-CA | Endometrial adenocarcinoma | Homo sapiens | CVCL_0028 | |
In-vivo Model | Six-week-old, female SCID-Berge mice were purchased from Vitalriver. EC cells with IGF2BP1 overexpression or silencing or the appropriate controls (1×106) were injected into lower abdominal cavity of each mouse (n = 5 mice/group). | |||
Endometrial cancer [ICD-11: 2C76]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | IGF2BP1 expression increased in EC, and high expression of this protein correlated with poor prognosis. IGF2BP1 can recognize m6A sites in the 3'UTR of PEG10 mRNA and recruits PABPC1 to enhance Retrotransposon-derived protein PEG10 (PEG10) mRNA stability, which consequently promotes PEG10 protein expression. | |||
Responsed Disease | Endometrial cancer [ICD-11: 2C76] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) | READER | ||
Target Regulation | Up regulation | |||
In-vitro Model | RL95-2 | Endometrial adenosquamous carcinoma | Homo sapiens | CVCL_0505 |
KLE | Endometrial adenocarcinoma | Homo sapiens | CVCL_1329 | |
Ishikawa | Endometrial adenocarcinoma | Homo sapiens | CVCL_2529 | |
HEC-1-B | Endometrial adenocarcinoma | Homo sapiens | CVCL_0294 | |
HEC-1-A | Endometrial adenocarcinoma | Homo sapiens | CVCL_0293 | |
AN3-CA | Endometrial adenocarcinoma | Homo sapiens | CVCL_0028 | |
In-vivo Model | Six-week-old, female SCID-Berge mice were purchased from Vitalriver. EC cells with IGF2BP1 overexpression or silencing or the appropriate controls (1×106) were injected into lower abdominal cavity of each mouse (n = 5 mice/group). | |||